Surgery Partners Will Report While Bain Capital Stays In and Everyone Else Gets Cashed Out

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Surgery Partners typically reports earnings before the market opens, meaning Day 0 reflects the first full trading session where investors react to results, and Day +1 captures follow-through momentum.

Surgery Partners has exhibited significant post-earnings volatility, with an average absolute Day 0 move of 5.32% and Day +1 move of 4.96%. The historical range is wide: Day 0 moves have ranged from a 25.42% decline (November 2025) to a 4.96% gain (May 2025), while Day +1 swings have included a 13.75% drop (November 2024) and a 12.34% decline (March 2026).

The most dramatic reaction came in November 2025, when the stock plunged 25.42% on earnings day—likely tied to the Q4 2025 miss and margin concerns—followed by a more muted 1.81% decline the next session. More recently, the August 2026 report (Q2 2026) saw a modest 2.70% Day 0 gain, followed by a 5.96% Day +1 decline, suggesting initial optimism gave way to profit-taking or renewed caution.

The data underscores that Surgery Partners is a high-volatility name around earnings, with investors reacting sharply to both beats and misses. Given the pending buyout at $23.50 per share, however, this quarter's price reaction may be more muted, as the stock is likely to trade within a narrow band around the deal price regardless of results.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of just 0.04% for the November 20 expiration, a negligible figure that reflects the market's view that the pending $23.50 buyout has effectively capped volatility. This stands in stark contrast to Surgery Partners' historical average post-earnings move of 5.32% on Day 0 and 4.96% on Day +1. The options market is signaling that earnings results are unlikely to materially move the stock, as the share price is anchored to the deal price rather than standalone fundamentals.

Part 3: What Analysts Are Saying

Surgery Partners currently holds a consensus analyst rating that translates to Hold, with an average price target of $21.25. The breakdown shows 2 Strong Buy ratings, 0 Moderate Buy, 8 Hold, 0 Moderate Sell, and 0 Strong Sell—a distribution that reflects the cautious, wait-and-see posture analysts have adopted following the merger announcement.

Analyst sentiment has deteriorated sharply over the past month. Just one month ago, the stock had 8 Strong Buy ratings, 1 Moderate Buy, and 4 Hold ratings, with an average recommendation of 4.31 (solidly in Buy territory). The current average of 3.40 represents a significant downgrade, driven by multiple firms cutting ratings to Hold as the pending buyout at $23.50 per share became the dominant valuation anchor.

The consensus price target of $21.25 sits 8.4% below the pending offer price and 8.4% below the current trading level, underscoring that analysts view the deal price as the primary driver of value rather than standalone fundamentals. The target range spans from a low of $15.00 to a high of $24.00, with the high estimate just modestly above the buyout price.

The sharp sentiment shift reflects the reality that Surgery Partners is now a deal stock rather than an operating story. Analysts have moved to the sidelines, with most firms acknowledging that the $23.50 offer effectively sets a floor and ceiling for the shares, leaving little room for traditional fundamental analysis to drive returns. The deterioration in ratings is less a reflection of worsening business fundamentals and more a recognition that the investment thesis has shifted entirely to deal execution and regulatory approval.

Part 4: Technical Picture

Surgery Partners enters earnings with a 100% Buy signal from the Barchart Technical Opinion, up from 88% Buy last week and a dramatic reversal from 72% Sell a month ago. The signal reflects maximum strength and a strengthening direction, driven by the stock's sharp rally following the October 26 buyout announcement.

Timeframe Analysis:

• Short-term (100% Buy): Maximum buy signal indicates near-term momentum is extremely positive, reflecting the market's embrace of the $23.50 buyout offer
• Medium-term (100% Buy): Strong buy signal across the intermediate timeframe suggests sustained bullish sentiment as the deal moves toward closing
• Long-term (100% Buy): Maximum buy signal in the longer-term view reflects confidence that the transaction will close at the announced price

Trend Characteristics: The opinion shows maximum strength and a strengthening direction, indicating that technical momentum is firmly positive heading into earnings—though this is almost entirely a function of the buyout rather than standalone chart dynamics.

The stock is trading above all key moving averages, a bullish technical setup. At the current level, Surgery Partners sits above the 5-day MA ($23.16), above the 10-day MA ($23.20), above the 20-day MA ($19.11), above the 50-day MA ($16.04), above the 100-day MA ($15.74), and above the 200-day MA ($14.81). The stock has rallied sharply from deeply oversold levels in recent weeks, with the technical picture transforming from bearish to maximum bullish in a matter of days.

The technical setup is overwhelmingly supportive heading into earnings, but it's critical to recognize that this is a deal-driven dynamic rather than a reflection of improving fundamentals. The stock's position above all moving averages and the maximum buy signal across all timeframes reflect the market's confidence that the HealthSpan Partners transaction will close at $23.50 per share. With the share price trading just below the offer price, the technical picture suggests limited downside risk (barring deal failure) but also minimal upside, as the buyout price effectively caps gains. For traders, the setup is neutral to slightly positive, with earnings results unlikely to drive meaningful volatility given the deal anchor.